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Recurrence or metastasis of cancer has been considered to occur in the last stage of the
patient’s life. However, the new notions of oligometastases and oligo-recurrence have been
proposed and the paradigm shift in the conceptualization of cancer metastasis or cancer
recurrence. Oligometastases is the state in which the patient shows distant relapse in only a
limited number of regions. Local therapy such as surgery, radiotherapy and radiofrequency
ablation for the relapsed sites could thus improve patient’s survival. On the other hand, oligo-
recurrence is a notion similar to oligometastases. However, the conditions of oligo-recurrence
has a primary site of the cancer controlled, meaning that all gross recurrent or metastatic
sites could be treated using local therapy.
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Recurrence or metastasis of cancer has usually been con-
sidered to occur in the last stage of the patient’s life. From
this perspective, even if only one site of recurrence or metas-
tasis is present, the cancer can be seeded throughout the
body hematogenously, meaning that local therapy cannot
eradicate all cancer cells. Systemic chemotherapy can then
only prolong life, rather than achieving cure. However,
Hellman and Weichselbaum proposed an alternative notion
in 1995, bringing about a paradigm shift in the conceptualiz-
ation of cancer metastasis or cancer recurrence. This new
notion is that of oligometastases (1).
OLIGOMETASTASES
Oligometastases is the state in which the patient shows
distant relapse in only a limited number of regions. Local
therapy such as surgery, radiotherapy and radiofrequency
ablation for the relapsed sites could thus improve patient’s
survival. The state of oligometastases (Fig. 1) represents an
important concept, but one important problem remains to be
solved. Oligometastases did not eliminate the uncontrolled
primary site with several distant metastases. Then, all meta-
static sites were thoroughly treated with local therapy, which
did not lead to disappearance of all gross tumors and not
might have achieved cure. As the primary site was not or
could not be treated with local therapy, the primary site
would exacerbate sooner.
OLIGO-RECURRENCE
Niibe et al. (2–4) proposed the new notion of
oligo-recurrence to overcome these problems. Oligo-
recurrence is a notion similar to oligometastases. However,
the conditions of oligo-recurrence are: (i) one to several
distant metastases/recurrences (usually one) in one to several
organs (usually one); (ii) primary site of the cancer con-
trolled; (iii) one to several distant metastases/recurrences can
be treated with local therapy; and (iv) no other distant metas-
tases/recurrences other than those in (iii). This state of
oligo-recurrence is shown in Fig. 2 and the differences
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Advance Access Publication 4 January 2010between oligometastasis and oligo-recurrence are listed in
Table 1. In the state of oligo-recurrence, recurrent or meta-
static sites with a controlled primary lesion were treated with
local therapy, meaning that all gross recurrent or metastatic
sites could be treated using local therapy.
SYSTEMIC THERAPY AND LOCAL THERAPY
Improvement of systemic chemotherapy including
molecular-targeted therapy has allowed micrometastases
to be almost completely absent clinically. Theoretically,
if several gross metastatic or recurrent sites could be era-
diated by local therapy, these patients could be cured
with concomitant systemic chemotherapy. Punglia et al.
(5) reported that if systemic therapy improved, the role of
local therapy would improve and proposed a ﬁgure for
this correlation. Here, a new ﬁgure of the correlation
between local therapy and systemic therapy is proposed
(Fig. 3), showing that the role of local therapy is initially
increasingly important as systemic therapy improves,
depending on the sigmoid curve. The current status of
cancer therapy lies in the range between 0 and
A. However, in the future, extreme improvements in sys-
temic therapy will decrease the importance of local
therapy, because cancers will be diminished by systemic
therapy alone such as intravenous anti-cancer drug infu-
sion or oral anti-cancer drugs. All cancerous lesions
including gross tumors and microinvasive tumors could
be eradicated with systemic therapy alone. This desirable
state is shown as B in Fig. 3. In the present status
(range: 0–A in Fig. 3), systemic therapy is not yet
powerful enough that local therapy is not required for
eradication, particularly for gross tumor.
Figure 1. This is a schema of oligometastases. Schema 1 shows one distant
metastasis/recurrence with a primary lesion. Schema 2 shows two distant
metastases/recurrences with a primary lesion.
Figure 2. This is a schema of oligo-recurrence. Schema 1 shows one distant
metastasis/recurrence with a controlled primary lesion. Schema 2 shows two
distant metastases/recurrences with a controlled primary lesion. The biggest
difference between oligometastases and oligo-recurrences lies in the uncon-
trolled or controlled primary lesion. Oligo-recurrence requires a controlled
primary lesion.






Primary lesion Uncontrolled/controlled Controlled
No. of distant/metastases/
recurrences
One to several One to several
(one is better)
Figure 3. This shows correlations between systemic and local therapies.
Until point A, the role of local therapy increases as systemic therapy
improves. However, after point A, the role of local therapy decreases as sys-
temic therapy improves, as all cancerous lesions can be cured by systemic
therapy at point B.
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This section and the following four sections focus on organ-
speciﬁc oligometastases and oligo-recurrence. First, oligome-
tastases and oligo-recurrence of brain metastatic tumors are
described.
Classiﬁcation of metastatic brain tumors such as
oligo-recurrence in recursive partitioning analysis (RPA)
class I is widely recognized and accepted (6). This class I
contains patients with: KPS 70; age ,65 years; controlled
primary; and no extracranial metastases. All RPA class I
patients thus show oligo-recurrence. However, RPA class I
requires age ,65 years, so if age is 65 years and even
KPS 100, the patient is classiﬁed as RPA class II. Rapid pro-
gress has recently been made in reducing the invasiveness of
surgery and radiotherapy. The age of 65 years is thus no
longer the limit of aggressive therapy. The RPA classiﬁ-
cation was developed in 1997, and more than a decade has
passed since the proposal of this classiﬁcation. Given recent
advances in modern medicine, oligo-recurrence is considered
to be more appropriate.
Kocher et al. (7) compared 117 patients with one to three
previously untreated cerebral metastases who underwent
stereotactic radiosurgery (SRS) between 1991 and 1998 with
138 patients with one to three lesions treated using whole-
brain radiotherapy (WBRT) between 1978 and 1991. The
ﬁrst modality represents a more powerful treatment of meta-
static brain tumors. Of these patients, 32 were classiﬁed as
RPA class I (SRS, n ¼ 23; WBRT, n ¼ 9). Median survival
was 25.4 months with SRS, compared with 4.7 months with
WBRT (P , 0.0001). Furthermore, Andrews et al. (8)
reported a Phase III trial comparing WBRT to WBRT plus
SRS, in which multivariate analysis indicated that patients
with WBRT plus SRS survived longer than those with
WBRT alone in RPA class I (P , 0.0001). These ﬁndings
suggest that more powerful local treatment was efﬁcacious
for RPA class I. As for oligo-recurrence involving the brain,
Niibe et al. (9) reported 17 metastatic brain tumors in 10
patients treated with SRS and surgery achieved 3-year local
control in 90% and 3-year overall survival in 51.9%.
LUNG TUMOR
Survival beneﬁts were being reported for complete resection
of metastatic lung tumors even in the 1990s. The
International Registry of Lung Metastases (IRLM) reported
that 5-year overall survival for patients with complete resec-
tion of metastatic lung tumors was 36%, compared with 13%
for patients without (10). However, clinical outcomes with
stereotactic body radiotherapy (SBRT) for Stage I primary
lung tumors are reportedly almost the same as with surgery.
Onihsi et al. (11) reported a 5-year overall survival of 70.8%
for operable Stage I patients, equivalent to that with surgery.
This indicates that oligo-recurrent patients, who have no
extrathoracic lesions, could receive survival beneﬁt from
SBRT. In fact, Bloomgren et al. (12) ﬁrst reported that 14
metastatic lung tumors in 10 patients treated with SBRT
achieved 92% local control. Uematsu et al. (13) reported
that 43 metastatic lung tumors in 22 patients treated with
SBRT achieved 98% local control. Nagata et al. (14) using
SBRT with 48 Gy in four fractions to the isocenter reported
that nine metastatic lung tumors in nine patients achieved
67% local control. From the same institution as Nagata,
Norihisa et al. (15) using SBRT at 48–60 Gy in four to ﬁve
fractions to the isocenter reported that 43 metastatic lung
tumors in 34 patients achieved a 2-year local control rate of
90% and a 2-year overall survival rate of 84.3%. These are
excellent outcomes. However, all these analyses were retro-
spective. In 2009, Rusthoven et al. (16) reported a Phase I/II
prospective study of SBRT for metastatic lung tumors.
Thirty-eight metastatic lung tumors in 63 patients treated
with SBRT achieved a 2-year local control rate of 96% and
a 2-year overall survival of 39%. This result was inferior to
that of surgery according to the IRLM. One of the important
reasons of poor prognosis in SBRT is that the prospective
study included patients with extrapulmonary lesions,
meaning oligometastases and no oligo-recurrence. Limited to
oligo-recurrence and the small numbers of lung metastases,
overall survival may be better and might be almost equival-
ent to that of the IRLM (16).
LIVER TUMOR
SBRT has also been applied to metastatic liver tumors. In
1998, Blomgren et al. reported that a pilot study using 20–
40 Gy in one or two fractions to the periphery of the plan-
ning target volume (PTV) achieved 95% local control (17).
Several prospective studies have recently been reported.
Herfarth et al. (18) reported 56 metastatic liver tumors in 33
patients treated with SBRT using 14–26 Gy per fraction
(prescribed to 80%), achieving 78% local control. Kavanagh
et al. (19) reported 28 metastatic liver tumors in 21 patients
treated with SBRT using 12–20 Gy in three fractions to the
periphery of the PTV, achieving 93% local control. Mendez
Romero et al. (20) reported 34 metastatic liver tumors in 14
patients treated with SBRT using 37.5 Gy in three fractions
(prescribed to 65%), achieving 94% local control. In 2009,
Rusthoven et al. (21) reported 63 metastatic liver tumors in
57 patients treated with SBRT using 36–60 Gy in three frac-
tions, achieving a 3-year local control rate of 92% and a
2-year overall survival rate of 30%.
BONE
Oligo-recurrence and oligometastases of bone have been
reported in breast cancer. The summary is that high-dose
radiotherapy relieves pain for a long time and can even
improve overall survival.
Niibe et al. (4) reported on solitary bone metastases in
seven patients treated with conventional radiotherapy. Six of
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was prolonged at the last follow-up. Only one patient
showed relapse of pain. This patient received 30 Gy in 10
fractions (BED10, 39 Gy), representing the smallest dose in
that series (other patients received 40–50 Gy in 20–25 frac-
tions; BED10  48 Gy). In 2009, Milano et al. (22) reported
85 metastatic lesions in 40 breast cancer patients treated with
SBRT, achieving a 2-year overall survival rate of 76% and a
4-year overall survival of 59%. Among these, the most
favorable prognostic factor for breast oligometastatic patients
was metastases only involving bone. This indicated high-
dose radiotherapy using SBRT for bone metastases could
contribute to patient survival.
LYMPH NODES
Oligometastases and oligo-recurrence of distant lymph node
metastases have been reported for uterine cervical carci-
noma. Uterine cervical carcinoma spreads through the lym-
phatic route rather than hematogenously (2,23). The ﬁrst site
of distant metastasis of uterine cervical carcinoma is the
para-aortic lymph node. This has been conﬁrmed in a large
population-based study (2).
Hong et al. (24) reported 35 patients with isolated para-
aortic lymph node recurrence treated with concurrent che-
moradiotherapy achieving a 5-year overall survival rate of
34%. Kim et al. (25) reported 12 patients treated with hyper-
fractionated radiotherapy totaling 60 Gy combined with con-
current chemoradiotherapy, achieving a 3-year overall
survival rate of 19%. To date, the largest study has been
reported by Niibe et al. (3) in Japan. They reported 84
patients treated with conventional radiotherapy with or
without chemotherapy achieved a 5-year overall survival rate
of 31.3%, similar to the 38% for 5-year overall survival rate
in a previous, small, population-based study in Japan (26).
Recently, Choi et al. (27) reported that 30 uterine cervical
and corpus cancer patients with isolated para-aortic lymph
node recurrence treated by SBRT using a cyberknife
achieved a 4-year overall survival of 50.1%.
CONCLUSIONS
Curative local therapy for oligometastases and
oligo-recurrence represents a brilliant opening to the era of
cancer therapy. Several decades ago, most metastatic and
recurrent cancer patients died within a year. However, we
cope with metastases or recurrences considering whether the
state is oligometastases or oligo-recurrence. In the state of
oligo-recurrence, all the gross tumors could be treated with
local therapy, meaning curative treatment. However, in the
state of oligometastases, clinicians should judge a primary
site to be controlled or not before treatment. If the primary
site is controlled, meaning oligo-recurrence, they should
pursue to cure the patients. However, if the primary site is
uncontrolled or extra-target metastases lesions exist, they
intend to prolong survival not to pursue cure.
More appropriate target cancers, treatment modalities and
schedules should be established for oligometastases and
oligo-recurrence. Moreover, adjuvant chemotherapy will
improve dramatically because of molecular-targeted drugs.
Further clinical studies are required in this ﬁeld.
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